Multiple myeloma Trials in Murcia, Spain
Conditions / Multiple myeloma / Murcia, Spain
Clinical trials for Multiple myeloma investigate a range of treatment strategies and patient populations.
42 total trials for this combination
Showing top 10 of 42 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04975997 | Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT00689936 | Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma | COMPLETED | PHASE3 |
| NCT06152575 | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | RECRUITING | — |
| NCT01734928 | Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | COMPLETED | PHASE3 |
| NCT04923893 | A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02181413 | A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant | COMPLETED | PHASE3 |
| NCT05827016 | A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | RECRUITING | PHASE3 |
| NCT01239797 | Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma | COMPLETED | PHASE3 |
| NCT02312258 | A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT) | COMPLETED | PHASE3 |
| NCT06679101 | A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) | RECRUITING | — |